NCT02424253View on ClinicalTrials.gov

A Study to Determine the Efficacy of ZPL-3893787 in Subjects With Atopic Dermatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

98

Participants

Timeline

Start Date

May 18, 2015

Primary Completion Date

January 31, 2016

Study Completion Date

February 3, 2016

Conditions
Atopic Dermatitis
Interventions
DRUG

ZPL-3893787

ZPL-3893787

DRUG

Placebo

Matched Placebo

Trial Locations (17)

Unknown

Belgium Study Site, Brussels

Belgium Study Site, Leuven

Belgium Study Site, Liège

German Study Site, Goch

German Study Site, Hamburg

German Study Site, Hanover

German Study Site, Mainz

German Study Site, Münster

Polish Study Site, Bialystok

Polish Study Site, Gdansk

Polish Study Site, Lodz

Polish Study Site, Poznan

Polish Study Site, Tarnów

UK Study Centre, Blackpool

UK Study Centre, Cannock

UK Study Centre, Leeds

UK Study Centre, Manchester

All Listed Sponsors
lead

Ziarco Pharma Ltd

INDUSTRY

NCT02424253 - A Study to Determine the Efficacy of ZPL-3893787 in Subjects With Atopic Dermatitis | Biotech Hunter | Biotech Hunter